Sermorelin dosing in research protocols: the diagnostic, acute, and frequent-dosing ranges
Sermorelin dosing in published research splits along three protocol categories: the historical diagnostic-test dose (single 1 μg/kg subcutaneous), acute pituitary-axis research protocols (single or short-course subcutaneous dosing), and frequent-dosing chronic-administration approaches (twice or thrice daily). The choice of protocol depends on what the research is measuring.
The historical diagnostic dose
Sermorelin received FDA approval in 1997 for paediatric GH-deficiency diagnostic use. The approved diagnostic protocol used a single subcutaneous dose of approximately 1 μg/kg of body weight, followed by serial GH-axis sampling at 15, 30, 45, 60, and 90 minutes post-injection. The acute GH-release peak indicated pituitary GH-axis competence; absence of a meaningful peak suggested pituitary-axis insufficiency.
The diagnostic protocol was withdrawn from the US market in 2008 along with the prescription-medicine status. The protocol is referenced here as historical fact relevant to research-protocol design for current acute pituitary-axis questions.
Acute pituitary-axis research protocols
Modern research-grade Sermorelin protocols investigating acute pituitary-axis function use similar single-dose serial-sampling designs. Common parameters:
- Dose: 1-2 μg/kg subcutaneous (50-200 μg for typical adult research populations).
- Sampling: baseline plus 15, 30, 45, 60, 90, 120 minutes for GH and IGF-1 measurement.
- Replicates: single dose vs paired-administration protocols (one Sermorelin + one placebo session with washout) for within-subject controls.
- Standardisation: fasted baseline preferred to minimise confounding from postprandial GH-axis state.
Frequent-dosing chronic-administration protocols
Research protocols using Sermorelin for chronic administration (multi-week or longer) compensate for the short half-life through frequent dosing. The most-common published approach:
- Dose per administration: 100-300 μg subcutaneous.
- Frequency: twice daily (typically morning and bedtime) or thrice daily.
- Total daily dose: 200-900 μg.
- Duration: 4-12 weeks for endpoint observation; some protocols extend to 6-12 months.
The frequent-dosing protocols are less standardised than the Tesamorelin daily-dose standard. The published evidence base for chronic Sermorelin administration in adult research populations is thinner than the corresponding Tesamorelin evidence; researchers should weigh the protocol-design considerations carefully.
Reconstitution math
Reconstitution for a typical 5 mg Sermorelin vial:
- 5 mg / 1 mL bacteriostatic water = 5 mg/mL = 5000 μg/mL. A 100 μg dose is 0.02 mL = 2 units on a U-100 insulin syringe (the lowest reasonable draw on a 30-unit syringe). A 300 μg dose is 0.06 mL = 6 units.
- 5 mg / 5 mL bacteriostatic water = 1 mg/mL = 1000 μg/mL. A 100 μg dose is 0.1 mL = 10 units; a 300 μg dose is 0.3 mL = 30 units (full 30u syringe). This is the cleaner concentration for the frequent-dosing protocols.
- 5 mg / 2.5 mL bacteriostatic water = 2 mg/mL = 2000 μg/mL. A 100 μg dose is 0.05 mL = 5 units; a 300 μg dose is 0.15 mL = 15 units.
The free reconstitution calculator handles the dose-volume math automatically.
Further reading
- Sermorelin parent overview.
- Sermorelin vs Tesamorelin — focused comparison.
- Sermorelin regulatory history.
- Tesamorelin dosing protocols (for comparison).
- Free reconstitution calculator.
Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.
Frequently asked questions
- What was the historical Sermorelin diagnostic dose?
- Approximately 1 μg/kg of body weight, given as a single subcutaneous dose. The protocol was followed by serial GH-axis sampling at 15, 30, 45, 60, and 90 minutes post-injection. The diagnostic protocol was withdrawn along with the US market withdrawal in 2008; the dose is referenced here as historical-protocol fact.
- What dose is used in modern Sermorelin research?
- Acute pituitary-axis research protocols use 1-2 μg/kg subcutaneous (50-200 μg for typical adult research populations). Chronic-administration research protocols use 100-300 μg twice or thrice daily; total daily dose ranges 200-900 μg. The chronic protocols are less standardised than the Tesamorelin once-daily standard.
- How is Sermorelin reconstituted?
- Bacteriostatic water diluent in 1-5 mL volumes for a typical 5 mg vial. The 5 mL volume produces 1 mg/mL = 1000 μg/mL — clean for the frequent-dosing protocols because a 100 μg dose is 0.1 mL = 10 units on a U-100 insulin syringe, and a 300 μg dose is 0.3 mL = 30 units (full 30-unit syringe).
- How is the dose drawn on a U-100 insulin syringe?
- U-100 syringes read in units where 100 units = 1 mL. For a 5 mg Sermorelin vial reconstituted in 5 mL (1 mg/mL = 1000 μg/mL), a 100 μg dose is 0.1 mL = 10 units; a 300 μg dose is 0.3 mL = 30 units. The free reconstitution calculator at /tools/reconstitution-calculator handles the math for non-standard reconstitution volumes.
- How long does a Sermorelin chronic-research protocol typically run?
- Published chronic-administration research protocols typically run 4-12 weeks for endpoint observation. Some protocols extend to 6-12 months for longer-term endpoints. The duration is shorter than the Tesamorelin standard (26-week phase-3 protocols) reflecting the thinner evidence base for long-duration Sermorelin administration.